About Eli Lilly and Company
Eli Lilly and Company (LLY) is a Healthcare company in the Pharmaceutical Preparations industry with a market capitalisation of $1T. The stock trades at 38.35x trailing earnings and yields 0.59%.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Market cap
- $1T
- P/E ratio
- 38.35
- EPS (TTM)
- $22.95
- Revenue (TTM)
- $65.2B
- Profit margin
- 31.7%
- Dividend yield
- 0.59%
- Shares outstanding
- 941.4M
Financial health: Strong8.8/10
7 strengths, 1 concern. Weakest points: debt to equity.
- Debt to equity: 1.60 (Concern, benchmark < 0.5) — Debt of 1.60x equity is high against the 0.5x benchmark. It has been broadly flat over the last 4 years.
- Current ratio: 1.58 (Strong, benchmark > 1.5) — Short-term assets cover 1.58x short-term liabilities, against Graham's 1.5x floor. It has improved over the last 4 years.
- Return on equity: 77.8% (Strong, benchmark > 15%) — Earns 77.8% on shareholder equity, comfortably past the > 15% mark.
- Gross margin: 83.4% (Strong, benchmark > 40%) — Keeps 83.4% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 31.7% (Strong, benchmark > 10%) — Turns 31.7% of revenue into profit, comfortably past the > 10% mark.
- Revenue growth: 44.7% (Strong, benchmark > 10%) — Revenue changed 44.7% year on year, comfortably past the > 10% mark.
- Earnings growth: 94.9% (Strong, benchmark > 10%) — Earnings changed 94.9% year on year, comfortably past the > 10% mark.
- Payout ratio: 26.1% (Strong, benchmark < 60%) — Pays out 26.1% of earnings as dividends, leaving room to keep paying.